Last updated: September 7, 2026
Edetate calcium disodium is a mature, low-volume injectable chelator used primarily for lead poisoning. Its commercial value comes from clinical necessity, limited supplier depth, hospital stocking requirements, and episodic shortage pricing rather than from large prescription volume. The product has no meaningful remaining branded exclusivity, no biosimilar exposure, and limited patent barriers. Public companies generally do not report revenue for edetate calcium disodium separately, so the drug’s financial trajectory must be assessed through demand drivers, supply conditions, procurement economics, and regulatory risk.
What is edetate calcium disodium used for?
Edetate calcium disodium, also known as calcium disodium EDTA or calcium disodium versenate, is an injectable chelating agent. The FDA-approved indication is the treatment of lead poisoning in adults and children, including patients with blood lead concentrations that require chelation therapy.[1]
The drug binds lead and promotes renal elimination. It is administered intravenously or intramuscularly under controlled clinical conditions. The FDA label warns against confusing edetate calcium disodium with disodium EDTA. The latter can produce severe hypocalcemia and has a different clinical risk profile.[1]
| Attribute |
Edetate calcium disodium |
| Active ingredient |
Calcium disodium edetate |
| Common names |
Edetate calcium disodium, calcium disodium EDTA, CaNa2EDTA |
| Therapeutic class |
Chelating agent |
| Primary approved use |
Lead poisoning |
| Dosage form |
Injectable solution |
| Common concentration |
200 mg/mL |
| Administration |
Intravenous or intramuscular |
| Primary setting |
Hospital, emergency, poison-control-directed care |
| Generic or branded market |
Predominantly generic or legacy branded supply |
| Biosimilar exposure |
None |
The product is not a routine outpatient medicine. Demand is linked to poisoning events, occupational exposure, contaminated products, public-health incidents, and the continued diagnosis of severe pediatric lead exposure.
What is the FDA regulatory status of edetate calcium disodium?
Edetate calcium disodium is an established FDA-approved drug with long-standing regulatory status. Its regulatory value is tied to the approved injectable formulation and manufacturing compliance, not to active exclusivity.
The FDA-approved label identifies the product for lead poisoning and sets dosing regimens based on the patient’s age, weight, clinical condition, and blood lead concentration.[1] Treatment is generally coordinated with toxicology specialists or poison control centers.
Is edetate calcium disodium an FDA-approved drug?
Yes. Edetate calcium disodium injection is FDA-approved for lead poisoning. The product is subject to standard requirements for injectable drug quality, sterility, container closure, labeling, and manufacturing controls.
The drug is also included in clinical guidance for severe lead exposure. The Centers for Disease Control and Prevention recommends chelation for selected patients with high blood lead levels, with treatment choice depending on the severity of exposure and clinical circumstances.[2]
Is edetate calcium disodium on the FDA drug shortage list?
The product has experienced supply constraints and shortage concerns in past periods. Injectable chelators are particularly vulnerable because the market is small, production is concentrated, and manufacturers may have limited commercial incentive to maintain redundant capacity. FDA shortage status can change as manufacturing, inventory, and allocation conditions change.[3]
A shortage does not necessarily indicate a long-term demand increase. For edetate calcium disodium, supply interruptions can reflect plant issues, component shortages, quality actions, limited production runs, or supplier decisions.
What patents protect edetate calcium disodium?
No material active patent estate is generally associated with the basic edetate calcium disodium molecule or its legacy injectable product. The compound and its medical use predate the modern pharmaceutical patent strategies used for new chemical entities.
| Protection category |
Commercial significance |
| Core compound patent |
No meaningful current barrier expected |
| Original composition patent |
Expired or commercially irrelevant |
| Basic lead-poisoning method patent |
No meaningful current exclusivity expected |
| Injectable formulation patent |
Limited likelihood of active blocking rights |
| Manufacturing patent |
Potentially relevant only to a specific process, supplier, or formulation |
| Pediatric exclusivity |
No current commercial significance |
| Orphan-drug exclusivity |
Not the principal market protection |
| Biosimilar exclusivity |
Not applicable |
Are there Orange Book patents for edetate calcium disodium?
The product’s commercial market is not generally protected by a current Orange Book patent estate comparable to that of newer branded drugs. Any patent listing must be evaluated against the specific reference product, National Drug Code, and current FDA Orange Book data because listings can differ by approved application and manufacturer.[4]
For market-entry analysis, the key conclusion is that a new applicant would face regulatory and manufacturing hurdles, not a strong composition-of-matter patent barrier.
Does edetate calcium disodium have Paragraph IV risk?
Paragraph IV litigation risk is low. A generic applicant normally uses an abbreviated new drug application and must address the reference product’s patent certifications. Where there are no meaningful unexpired patents listed against the relevant reference product, Paragraph IV litigation is unlikely to be the principal barrier.
The more relevant risks are:
- FDA approval timing
- Injectable manufacturing validation
- Sterility and quality controls
- Limited market size
- Contracting with hospitals and distributors
- Reliable active pharmaceutical ingredient supply
- Inventory economics during non-shortage periods
When does edetate calcium disodium lose exclusivity?
Edetate calcium disodium lost practical exclusivity decades ago. It is a legacy small-molecule injectable with generic competition and no commercially important remaining period of new-drug exclusivity.
| Exclusivity type |
Current position |
| New chemical entity exclusivity |
Expired |
| Orphan exclusivity |
No meaningful current protection |
| Pediatric exclusivity |
Expired or not commercially determinative |
| Data exclusivity |
Expired |
| Patent exclusivity |
No material current barrier generally associated with the core product |
| Reference-product market protection |
Minimal |
The market therefore behaves as a mature essential-drug market rather than as a protected specialty pharmaceutical market.
How large is the edetate calcium disodium market?
The global market is small relative to mainstream hospital injectables and substantially smaller than the markets for oral lead-chelation products. Public market-research estimates vary because analysts may combine calcium disodium EDTA with disodium EDTA, succimer, dimercaprol, or the broader heavy-metal chelation market.
A reliable standalone global revenue figure is not generally disclosed by manufacturers, distributors, or public companies. Product-level sales are usually immaterial within the reporting segments of diversified pharmaceutical companies.
What drives demand for edetate calcium disodium?
Demand is shaped by clinical events rather than prescription growth. The principal drivers are:
- Severe pediatric or adult lead poisoning.
- Occupational and environmental lead exposure.
- Public-health investigations involving contaminated housing, soil, water, food, or consumer products.
- Hospital preparedness and antidote stocking.
- Poison-control recommendations.
- Limited substitution options for severe lead poisoning.
The drug has a low-frequency, high-importance demand profile. Hospitals may need to stock the product even when annual utilization is minimal.
How does lead exposure affect the commercial market?
Lead exposure remains a public-health issue, especially in older housing and communities with industrial contamination. CDC guidance has lowered the blood lead reference value over time as evidence of harm at lower concentrations has accumulated.[2] That change increases testing and case identification but does not translate directly into equivalent growth in edetate calcium disodium sales. Many patients with elevated lead levels do not require injectable chelation.
The market is therefore more sensitive to the number of severe cases than to the total number of patients with detectable lead exposure.
How does edetate calcium disodium compare with competing chelation drugs?
Edetate calcium disodium competes within a narrow therapeutic category. The alternatives differ by route, indication, toxicity profile, and severity of poisoning.
| Drug |
Main role |
Route |
Commercial relationship |
| Edetate calcium disodium |
Severe lead poisoning |
IV or IM |
Direct injectable competitor |
| Succimer |
Mild to moderate lead poisoning in selected patients |
Oral |
Main practical substitute in less severe cases |
| Dimercaprol |
Severe lead poisoning, often with encephalopathy, and selected metal poisonings |
IM |
Often used in combination with edetate calcium disodium |
| Penicillamine |
Selected chronic metal poisonings |
Oral |
Limited alternative use |
| Disodium EDTA |
Different chelation product and risk profile |
IV |
Not interchangeable with calcium disodium EDTA |
Succimer can reduce demand for injectable edetate calcium disodium when patients qualify for oral therapy. Dimercaprol can increase demand for edetate calcium disodium in severe cases because the two drugs may be used together under specialist direction.[2]
The product does not face conventional biologic competition. Biosimilar development is irrelevant because edetate calcium disodium is a chemically synthesized small molecule.
What formulations are protected by edetate calcium disodium patents?
The commercially important formulation is an injectable aqueous solution, commonly supplied at 200 mg/mL in single-dose containers. There is no widely recognized current formulation patent strategy that materially protects the standard product.
Potential formulation barriers are operational rather than exclusivity-based. A manufacturer must demonstrate:
- Sterility assurance
- Container and closure compatibility
- Stability over the labeled shelf life
- Correct calcium-to-EDTA composition
- Control of elemental impurities
- Consistent concentration and pH
- Extractables and leachables compliance
- Reliable fill-finish capacity
These requirements can deter entry even when patents do not.
Who manufactures or supplies edetate calcium disodium?
Supply has historically involved generic injectable manufacturers and legacy branded product channels. Manufacturer participation can change because the market is small and the product may be discontinued, transferred, or supplied through a contract-manufacturing arrangement.
The relevant competitive set includes:
- Generic injectable manufacturers
- Hospital-distribution suppliers
- Contract manufacturers
- Government and public-health procurement channels
- Specialty pharmaceutical distributors
Hospitals typically purchase through group purchasing organizations, wholesalers, direct contracts, or shortage-allocation channels. A supplier with dependable inventory can obtain disproportionate commercial value despite low absolute market volume.
What is the financial trajectory for edetate calcium disodium?
The drug’s financial trajectory is best described as stable-to-volatile at the product level and immaterial at the diversified-company level.
| Financial factor |
Effect on revenue |
| Severe lead-poisoning incidence |
Supports baseline demand |
| Low treatment frequency |
Limits volume growth |
| Generic competition |
Compresses ordinary pricing |
| Limited supplier base |
Can support temporary price increases |
| Shortages |
Create episodic revenue spikes and procurement premiums |
| Hospital stocking |
Supports recurring baseline orders |
| Injectable manufacturing costs |
Limits margin at low production volumes |
| No active exclusivity |
Restricts sustained premium pricing |
| Public-health events |
Can create short-term demand surges |
A supplier may earn attractive margins during shortage periods, but those margins are difficult to sustain. Once multiple suppliers restore inventory, purchasing organizations and hospitals generally push pricing toward generic injectable norms.
Is edetate calcium disodium a material revenue product?
For a diversified pharmaceutical company, probably not. The drug is unlikely to be reported as a separate revenue line unless it is part of a narrowly focused hospital-products portfolio. Public financial disclosures usually group such products within broader categories such as generic injectables, hospital products, or specialty pharmaceuticals.
The principal financial value may lie in portfolio completeness, hospital-account access, and supply reliability rather than in standalone sales scale.
What generic entry risks exist for edetate calcium disodium?
Generic entry risk is structurally high because the molecule is old and patent protection is weak. That risk is moderated by the small market and manufacturing complexity.
Likely generic launch scenarios
| Scenario |
Market effect |
| New entrant enters during adequate supply |
Lower prices and weaker incumbent share |
| New entrant enters during shortage |
Rapid uptake and improved supply resilience |
| One incumbent exits |
Higher shortage and allocation risk |
| Multiple manufacturers remain active |
Stable pricing with limited margin expansion |
| FDA quality action affects a supplier |
Temporary market disruption and price volatility |
A new generic entrant may not pursue the product unless it can obtain dependable API supply, secure sterile manufacturing capacity, and achieve sufficient hospital distribution. Regulatory approval alone does not guarantee economic success.
What patent litigation and settlement agreements affect the market?
There is no well-known current patent litigation pattern comparable to major branded medicines. Paragraph IV litigation and settlement agreements are not central to the commercial outlook for edetate calcium disodium.
The more relevant legal and regulatory disputes would involve:
- Product liability
- Labeling and medication-error allegations
- Manufacturing quality
- Drug-shortage reporting
- Contracting and allocation
- Compounding or unauthorized distribution
- False or misleading claims for non-approved chelation uses
FDA-approved use should be distinguished from unapproved promotional claims. Calcium disodium EDTA has periodically been marketed or discussed for cardiovascular and atherosclerosis-related chelation uses, but those uses do not define the FDA-approved commercial market.[1]
How strong is the patent estate for edetate calcium disodium?
The patent estate is weak. Commercial defensibility depends on execution.
| Patent-estate metric |
Assessment |
| Composition-of-matter protection |
Weak or expired |
| Method-of-use protection |
Weak for approved lead indication |
| Formulation protection |
Limited |
| Manufacturing know-how |
Potentially meaningful |
| Regulatory barriers |
Moderate for sterile injectable approval |
| Supply-chain barriers |
Moderate to high |
| Brand loyalty |
Low |
| Hospital switching costs |
Moderate during shortages, low during adequate supply |
The strongest assets are likely to be manufacturing know-how, validated sterile capacity, supply reliability, distribution relationships, and inclusion in hospital formularies.
What is the outlook for edetate calcium disodium?
The outlook is a mature essential-medicine niche with low structural growth and recurring supply volatility. Demand should remain resilient because severe lead poisoning will continue to require chelation and hospitals must maintain access to approved therapy.
Revenue growth is unlikely to come from broad patient expansion. Upside depends on:
- Shortage conditions
- Government procurement
- New hospital contracts
- Improved distribution
- Price increases during constrained supply
- Portfolio bundling with other antidotes and hospital injectables
Downside risks include supplier withdrawal, FDA quality actions, generic price erosion, substitution with succimer in eligible patients, and low utilization relative to the cost of maintaining sterile production.
Key Takeaways
- Edetate calcium disodium is an FDA-approved injectable treatment for severe lead poisoning.
- It is a mature generic product with no meaningful current core patent protection.
- Orange Book and Paragraph IV issues are secondary to sterile manufacturing and supply reliability.
- The drug has no biosimilar risk because it is a small-molecule chelator.
- Standalone revenue is not generally disclosed and is likely immaterial within diversified pharmaceutical companies.
- The commercial market is small, clinically important, and vulnerable to shortages.
- Pricing can rise sharply during supply interruptions but is difficult to sustain after supply normalizes.
- Succimer and dimercaprol are the most relevant clinical alternatives, although they are not fully interchangeable.
- The strongest competitive advantages are validated injectable capacity, API access, hospital distribution, and dependable inventory.
- Long-term growth is limited; financial performance will remain driven by supply events and procurement conditions.
FAQs About Edetate Calcium Disodium Market and Exclusivity
Is edetate calcium disodium still commercially available?
It remains an established hospital injectable, but availability can vary by manufacturer, wholesaler inventory, and FDA shortage conditions.
Can a pharmaceutical company obtain new exclusivity for edetate calcium disodium?
A company could pursue regulatory exclusivity only through a qualifying new approval or legally available designation. The basic old drug does not retain original new-chemical-entity exclusivity.
Is calcium disodium EDTA the same as disodium EDTA?
No. They have different calcium content, clinical uses, and safety risks. Medication errors between the products can cause serious harm.[1]
Does edetate calcium disodium treat cardiovascular disease?
Its FDA-approved indication is lead poisoning. Use for other conditions requires separate clinical and regulatory analysis and is not the basis of the approved product market.
What would make edetate calcium disodium financially attractive to a manufacturer?
The strongest commercial case would involve reliable sterile capacity, shortage-resilient supply, hospital distribution, and a broader portfolio of antidotes or generic injectables. Standalone volume is unlikely to justify a large dedicated commercial infrastructure.
References
-
U.S. Food and Drug Administration. (n.d.). Edetate calcium disodium injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
Centers for Disease Control and Prevention. (n.d.). Recommended actions based on blood lead level. https://www.cdc.gov/lead-prevention/
-
U.S. Food and Drug Administration. (n.d.). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
